MediumBank Biotechnology

Explore the latest insights on MediumBank Biotechnology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of MediumBank Biotechnology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Xinhua Pharmaceutical Secures NMPA Registration for Generic Sacubitril/Valsartan Tablets – Entering China's RMB 7.8 Billion Heart Failure Market
CompanyDrug

Xinhua Pharmaceutical Secures NMPA Registration for Generic Sacubitril/Valsartan Tablets – Entering China’s RMB 7.8 Billion Heart Failure Market

Shandong Xinhua Pharmaceutical Company Limited (HKG: 0719, SHE: 000756) announced that it has received a Drug Registration Certificate from China's National Medical Products Administration (NMPA) for Sacubitril/Valsartan Sodium Tablets (sacubitril…

SSY Group Secures NMPA Approval for Nimodipine Oral Solution – Bulk Drug‑to‑Formulation Vertical Integration Strengthens Cerebrovascular Portfolio

Novartis' Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism

Novartis’ Rhapsido (Remibrutinib) Wins FDA Approval – First‑in‑Class BTK Inhibitor Becomes First Approved Treatment for Symptomatic Dermographism

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
ACROBiosystems and MediumBank Forge Strategic Partnership on AI‑Designed Proteins – Closed‑Loop Program Targets Thermostable bFGF and High‑Activity Cytokines for Cell Culture Media
CompanyDeals

ACROBiosystems and MediumBank Forge Strategic Partnership on AI‑Designed Proteins – Closed‑Loop Program Targets Thermostable bFGF and High‑Activity Cytokines for Cell Culture Media